Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001

BIOLOGICAL2 trials

Sponsors

Guangzhou Patronus Biotech Co., Ltd.

Conditions

COVID-19

Phase 3

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

Guangzhou Patronus Biotech Co., Ltd.COVID-19

Start: 2022-12-28End: 2023-12-31Updated: 2023-09-26

Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

TerminatedNCT05683600

Guangzhou Patronus Biotech Co., Ltd.COVID-19

Start: 2022-12-29End: 2023-07-12Updated: 2023-09-28

Related Papers

Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial

Expert Review of Vaccines2024-12-251 citations